Early switch from run-in treatment with vemurafenib plus cobimetinib to atezolizumab after 3 months leads to rapid loss of tumour control in patients with advanced BRAFV600-positive melanoma: The ImmunoCobiVem phase 2 randomised trial-Reference-Cited by-同舟云学术

Early switch from run-in treatment with vemurafenib plus cobimetinib to atezolizumab after 3 months leads to rapid loss of tumour control in patients with advanced BRAFV600-positive melanoma: The ImmunoCobiVem phase 2 randomised trial

Published:2023-09 Issue: Volume:190 Page:112941
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Livingstone E.,Gogas H.^ORCID,Kandolf-Sekulovic L.,Meier F.^ORCID,Eigentler T.K.,Ziemer M.^ORCID,Terheyden P.A.M.,Gesierich A.H.,Herbst R.A.,Kähler K.C.,Ziogas D.C.,Mijuskovic Z.^ORCID,Garzarolli M.,Garbe C.,Roesch A.^ORCID,Ugurel S.,Gutzmer R.^ORCID,Grob J.J.,Kiecker F.,Utikal J.,Windemuth-Kieselbach C.,Eckhardt S.,Zimmer L.^ORCID,Schadendorf D.^ORCID

Funder

University Hospital Essen

F. Hoffmann-La Roche

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference23 articles.

1. Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600–mutant melanoma;Ascierto;Eur J Cancer,2020

2. Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma;Robert;N Engl J Med,2019

3. Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma;Wolchok;J Clin Oncol,2022

4. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study;Robert;Lancet Oncol,2019

5. COLUMBUS 5-year update: a randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma;Dummer;J Clin Oncol,2022